- Author:
Guili ZHANG
1
;
Fei DONG
1
;
Caifu LUAN
1
;
Xia ZHANG
1
;
Huiyuan SHAO
1
;
Jie LIU
1
;
Chengming SUN
1
Author Information
- Publication Type:Journal Article
- MeSH: Blast Crisis; Bone Marrow; CCAAT-Enhancer-Binding Protein-alpha; metabolism; Case-Control Studies; Cell Cycle; Cell Proliferation; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; metabolism; Transfection
- From: Chinese Journal of Hematology 2015;36(11):947-950
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the expression and the possible mechanism of the transcription factor C/EBPα in chronic myeloid leukemia(CML).
METHODSBone marrow samples from 50 CML patients(including 33 patients in chronic phase, 7 in accelerated phase and 10 in blast crisis)and peripheral blood specimens of 20 healthy donors were collected. The expression of C/EBPα gene and the effect of Imatinib on its expression was detected by RT- PCR. C/EBPα gene was inserted into lentivirus expression vector pLVX- EGFP- 3FLAG- Puro by recombinant DNA technology to construct C/EBPα stable expression in K562 cells. Cell proliferation was assayed by CCK-8. The expressions of Foxo3a and Bim genes were detected by RT-PCR.
RESULTSThe level of C/EBPα expression was significantly declined in CML patients compared with that of normal control group(P<0.01)and had negative correlation with bcr- abl expression(Spearman r=- 0.505, P<0.01). The stable K562- C/EBPα cell line was successfully established and confirmed by RT-PCR and Western blot. Cell proliferation ability was lower in the K562- C/EBPα group than that in the non- transfection and mock-vehicle groups. The expressions of Foxo3a and Bim genes were 1.06 ± 0.06 and 0.53 ± 0.07, respectively, which was higher than that of nontransfection and mock-vehicle groups(P<0.01, P<0.05).
CONCLUSIONC/EBPα expression was decreased in CML patients, overexpression of C/EBPα could inhibit K562 cell growth.